IMMUNITYBIO, INC. (IBRX) Return on equity 2016–2019
IMMUNITYBIO, INC. (IBRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-966.4%FY2019 · since FY2016: -41.2% → -966.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2019 | -966.4% | -849.0 pp |
| FY2018 | -117.4% | -73.4 pp |
| FY2017 | -44.1% | -2.9 pp |
| FY2016 | -41.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Gross marginIBRX Operating incomeIBRX Operating marginIBRX Operating cash flowIBRX Free cash flowIBRX Capital expendituresIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →